Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Lack of anti-tumour reactivity despite enhanced numbers of circulating natural killer T cells in two patients with metastatic renal cell carcinoma.

Vyth-Dreese FA, Sein J, van de Kasteele W, Dellemijn TA, van den Bogaard C, Nooijen WJ, de Gast GC, Haanen JB, Bex A.

Clin Exp Immunol. 2010 Dec;162(3):447-59. doi: 10.1111/j.1365-2249.2010.04274.x. Epub 2010 Oct 5.

2.

Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.

Luiten RM, Kueter EW, Mooi W, Gallee MP, Rankin EM, Gerritsen WR, Clift SM, Nooijen WJ, Weder P, van de Kasteele WF, Sein J, van den Berk PC, Nieweg OE, Berns AM, Spits H, de Gast GC.

J Clin Oncol. 2005 Dec 10;23(35):8978-91. Epub 2005 Oct 31.

PMID:
16260696
3.

Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma.

Verra N, Jansen R, Groenewegen G, Mallo H, Kersten MJ, Bex A, Vyth-Dreese FA, Sein J, van de Kasteele W, Nooijen WJ, de Waal M, Horenblas S, de Gast GC.

Br J Cancer. 2003 May 6;88(9):1346-51.

4.

Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma.

de Gast GC, Batchelor D, Kersten MJ, Vyth-Dreese FA, Sein J, van de Kasteele WF, Nooijen WJ, Nieweg OE, de Waal MA, Boogerd W.

Br J Cancer. 2003 Jan 27;88(2):175-80.

5.

Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.

Bardelmeijer HA, Beijnen JH, Brouwer KR, Rosing H, Nooijen WJ, Schellens JH, van Tellingen O.

Clin Cancer Res. 2000 Nov;6(11):4416-21.

6.

Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.

de Gast GC, Klümpen HJ, Vyth-Dreese FA, Kersten MJ, Verra NC, Sein J, Batchelor D, Nooijen WJ, Schornagel JH.

Clin Cancer Res. 2000 Apr;6(4):1267-72.

7.

Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice.

van Tellingen O, Beijnen JH, Verweij J, Scherrenburg EJ, Nooijen WJ, Sparreboom A.

Clin Cancer Res. 1999 Oct;5(10):2918-24.

8.

Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.

van Tellingen O, Huizing MT, Panday VR, Schellens JH, Nooijen WJ, Beijnen JH.

Br J Cancer. 1999 Sep;81(2):330-5.

9.

At home management of aplastic phase following high-dose chemotherapy with stem-cell rescue for hematological and non-hematological malignancies.

Westermann AM, Holtkamp MM, Linthorst GA, van Leeuwen L, Willemse EJ, van Dijk WC, Nooijen WJ, Baars JW, Schornagel JH, Rodenhuis S.

Ann Oncol. 1999 May;10(5):511-7.

PMID:
10415999
10.

High-performance liquid chromatographic bio-analysis of PSC 833 in human and murine plasma.

van Tellingen O, Kemper M, Tijssen F, van Asperen J, Nooijen WJ, Beijnen JH.

J Chromatogr B Biomed Sci Appl. 1998 Nov 20;719(1-2):251-7.

PMID:
9869389
11.

Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.

Rodenhuis S, Richel DJ, van der Wall E, Schornagel JH, Baars JW, Koning CC, Peterse JL, Borger JH, Nooijen WJ, Bakx R, Dalesio O, Rutgers E.

Lancet. 1998 Aug 15;352(9127):515-21.

PMID:
9716055
12.

Comparative pharmacology of the novel cyclopropylpyrroloindole-prodrug carzelesin in mice, rats, and humans.

van Tellingen O, Nooijen WJ, Schaaf LJ, van der Valk M, van Asperen J, Henrar RE, Beijnen JH.

Cancer Res. 1998 Jun 1;58(11):2410-6.

13.

A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study.

van Tellingen O, Punt CJ, Awada A, Wagener DJ, Piccart MJ, Groot Y, Schaaf LJ, Henrar RE, Nooijen WJ, Beijnen JH.

Cancer Chemother Pharmacol. 1998;41(5):377-84.

PMID:
9523733
14.

Preclinical pharmacokinetics of paclitaxel and docetaxel.

Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH.

Anticancer Drugs. 1998 Jan;9(1):1-17. Review.

PMID:
9491787
15.

Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.

Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, Borst P, Nooijen WJ, Beijnen JH, van Tellingen O.

Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):2031-5.

16.

Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.

van Asperen J, van Tellingen O, Sparreboom A, Schinkel AH, Borst P, Nooijen WJ, Beijnen JH.

Br J Cancer. 1997;76(9):1181-3.

17.

The vascular compartment hampers accurate determination of teniposide penetration into brain tumor tissue.

van Tellingen O, Boogerd W, Nooijen WJ, Beijnen JH.

Cancer Chemother Pharmacol. 1997;40(4):330-4.

PMID:
9225951
18.

Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice.

van Asperen J, Schinkel AH, Beijnen JH, Nooijen WJ, Borst P, van Tellingen O.

J Natl Cancer Inst. 1996 Jul 17;88(14):994-9.

PMID:
8667431
19.

Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography.

Sparreboom A, van Tellingen O, Huizing MT, Nooijen WJ, Beijnen JH.

J Chromatogr B Biomed Appl. 1996 Jun 7;681(2):355-62.

PMID:
8811447
20.

Isolation, purification and biological activity of major docetaxel metabolites from human feces.

Sparreboom A, Van Tellingen O, Scherrenburg EJ, Boesen JJ, Huizing MT, Nooijen WJ, Versluis C, Beijnen JH.

Drug Metab Dispos. 1996 Jun;24(6):655-8.

PMID:
8781781
21.

Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer.

Rodenhuis S, Westermann A, Holtkamp MJ, Nooijen WJ, Baars JW, van der Wall E, Slaper-Cortenbach IC, Schornagel JH.

J Clin Oncol. 1996 May;14(5):1473-83.

PMID:
8622061
22.

Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.

Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH.

Cancer Res. 1996 May 1;56(9):2112-5.

23.

Tissue distribution, metabolism and excretion of paclitaxel in mice.

Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH.

Anticancer Drugs. 1996 Jan;7(1):78-86.

PMID:
8742102
24.

Unchanged pharmacokinetics of etoposide given by intra-arterial hepatic infusion as compared with i.v. infusion.

van Tellingen O, Kuck MT, Vlasveld LT, Rodenhuis S, Nooijen WJ, Beijnen JH.

Cancer Chemother Pharmacol. 1996;38(4):387-90.

PMID:
8674164
25.

High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach.

van der Wall E, Nooijen WJ, Baars JW, Holtkamp MJ, Schorangel JH, Richel DJ, Rutgers EJ, Slaper-Cortenbach IC, van der Schoot CE, Rodenhuis S.

Br J Cancer. 1995 Apr;71(4):857-62.

26.

Determination of paclitaxel and metabolites in mouse plasma, tissues, urine and faeces by semi-automated reversed-phase high-performance liquid chromatography.

Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH.

J Chromatogr B Biomed Appl. 1995 Feb 17;664(2):383-91.

PMID:
7780591
27.

Isolation, purification, and biological activity of mono- and dihydroxylated paclitaxel metabolites from human feces.

Sparreboom A, Huizing MT, Boesen JJ, Nooijen WJ, van Tellingen O, Beijnen JH.

Cancer Chemother Pharmacol. 1995;36(4):299-304.

PMID:
7628049
28.

Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: effect of graft size.

van der Wall E, Richel DJ, Holtkamp MJ, Slaper-Cortenbach IC, van der Schoot CE, Dalesio O, Nooijen WJ, Schornagel JH, Rodenhuis S.

Ann Oncol. 1994 Nov;5(9):795-802.

PMID:
7531486
29.

Fully automated high-performance liquid chromatographic method for the determination of carzelesin (U-80,244) and metabolites (U-76,073 and U-76,074) in human plasma.

van Tellingen O, Pels EM, Henrar RE, Schaaf LJ, Padbury GE, Beijnen JH, Nooijen WJ.

J Chromatogr. 1994 Jan 14;652(1):51-8.

PMID:
8014227
30.

Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinleucinol in mice as determined by high-performance liquid chromatography.

van Tellingen O, Sonneveldt AL, Beijnen JH, Nooijen WJ, Kettenes-van den Bosch JJ, Versluis C, Bult A.

Cancer Chemother Pharmacol. 1994;33(5):425-34.

PMID:
8306418
31.

The pharmacokinetics of reduced folates after intraperitoneal and intravenous administration of racemic [6S,R]-folinic acid.

Sips JH, van Tellingen O, Nooijen WJ, Rodenhuis S, Ten Bokkel Huinink WJ, Beijnen JH.

Cancer Chemother Pharmacol. 1994;35(2):144-8.

PMID:
7987991
33.

Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinorelbine in mice as determined by high performance liquid chromatography.

van Tellingen O, Kuijpers AV, Beijnen JH, Nooijen WJ, Bult A.

Invest New Drugs. 1993 May-Aug;11(2-3):141-50.

PMID:
8262726
34.

Tissue disposition, excretion and metabolism of vinblastine in mice as determined by high-performance liquid chromatography.

van Tellingen O, Beijnen JH, Nooijen WJ, Bult A.

Cancer Chemother Pharmacol. 1993;32(4):286-92.

PMID:
8324870
35.

Insulin resistance and breast-cancer risk.

Bruning PF, Bonfrèr JM, van Noord PA, Hart AA, de Jong-Bakker M, Nooijen WJ.

Int J Cancer. 1992 Oct 21;52(4):511-6.

PMID:
1399128
36.

Pharmacology, bio-analysis and pharmacokinetics of the vinca alkaloids and semi-synthetic derivatives (review).

van Tellingen O, Sips JH, Beijnen JH, Bult A, Nooijen WJ.

Anticancer Res. 1992 Sep-Oct;12(5):1699-715. Review.

PMID:
1444238
37.

Body measurements, estrogen availability and the risk of human breast cancer: a case-control study.

Bruning PF, Bonfrèr JM, Hart AA, van Noord PA, van der Hoeven H, Collette HJ, Battermann JJ, de Jong-Bakker M, Nooijen WJ, de Waard F.

Int J Cancer. 1992 Apr 22;51(1):14-9.

PMID:
1563834
38.

Breast cancer mucin: an automated assay to detect mucus glycoproteins.

Bonfrer JM, de Graaf HM, Nooijen WJ.

Tumour Biol. 1992;13(3):162-7.

PMID:
1626180
39.

Thyroid function 10-18 years after mantle field irradiation for Hodgkin's disease.

Peerboom PF, Hassink EA, Melkert R, DeWit L, Nooijen WJ, Bruning PF.

Eur J Cancer. 1992;28A(10):1716-8.

PMID:
1389492
41.

Radiation injury in the human kidney: a prospective analysis using specific scintigraphic and biochemical endpoints.

Dewit L, Anninga JK, Hoefnagel CA, Nooijen WJ.

Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):977-83.

PMID:
1976615
42.

Impaired mitochondrial respiration and stimulated glycolysis by m-iodobenzylguanidine (MIBG).

Loesberg C, Van Rooij H, Nooijen WJ, Meijer AJ, Smets LA.

Int J Cancer. 1990 Aug 15;46(2):276-81.

PMID:
2384275
43.

A simple method for the measurement of the steroid fraction bound to sex hormone binding globulin in serum.

Bonfrer JM, Bruning PF, Nooijen WJ.

J Steroid Biochem. 1989 Aug;33(2):227-31.

PMID:
2770298
44.

Low dose aminoglutethimide without hydrocortisone for the treatment of advanced postmenopausal breast cancer.

Bruning PF, Bonfrer JM, Hart AA, van der Linden E, de Jong-Bakker M, Moolenaar AJ, Nooijen WJ.

Eur J Cancer Clin Oncol. 1989 Feb;25(2):369-76.

PMID:
2702989
45.

Glucagon receptors: are they present on human blood cells?

van Hinsbergh VW, Nooijen WJ, Kempen HJ.

Horm Metab Res. 1982 Feb;14(2):65-8.

PMID:
6279478
46.

Recalculation of calcium-binding properties of human and rat fibrin(ogen) and their degradation products.

Nieuwenhuizen W, van Ruijven-Vermeer IA, Nooijen WJ, Vermond A, Haverkate F, Hermans J.

Thromb Res. 1981 Jun 1-25;22(5-6):653-7. No abstract available.

PMID:
7302909
47.

Radioimmunoassay for pancreatic glucagon based on specific derivatisation of the hormone.

Nooijen WJ, Koppert PW.

Ann Clin Biochem. 1981 Mar;18 (Pt 2):118-22.

PMID:
6167195
48.

Immunogenicity and bioactivity of glucagon, modified at methionine-27.

Nooijen WJ, Kempen HJ.

Horm Metab Res. 1979 Aug;11(8):459-63.

PMID:
227776
49.

Calcium-binding properties of human fibrin(ogen) and degradation products.

Nieuwenhuizen W, Vermond A, Nooijen WJ, Haverkate F.

FEBS Lett. 1979 Feb 15;98(2):257-9. No abstract available.

50.

Ca binding of rat fibrinogen and fibrin(ogen) degradation products.

van Ruijven-Vermeer IA, Nieuwenhuizen W, Nooijen WJ.

FEBS Lett. 1978 Sep 1;93(1):177-80. No abstract available.

Supplemental Content

Loading ...
Support Center